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Abstract
 
We evaluated the proposal that during microbial infection, dendritic cells (DCs) undergo
maturation and present a mixture of peptides derived from the microbe as well as harmless
environmental antigens. Mice were exposed to an aerosol of endotoxin free ovalbumin
(OVA) in the absence or presence of influenza virus. In its absence, OVA failed to induce B
and T cell responses and even tolerized, but with influenza, OVA-specific antibodies and
CD8
 
 
 
 cytolytic T lymphocytes developed. With or without infection, OVA was presented
selectively in the draining mediastinal lymph nodes, as assessed by the comparable prolifera-
tion of infused, CD8
 
 
 
 and CD4
 
 
 
, TCR transgenic T cells. In the absence of influenza, these
OVA-specific T cells produced little IL-2, IL-4, IL-10, and IFN-
 
 
 
, but with infection, both
CD4
 
 
 
 and CD8
 
 
 
 T cells made high levels of IL-2 and IFN-
 
 
 
. The OVA plus influenza-
treated mice also showed accelerated recovery to a challenge with recombinant vaccinia OVA
virus. CD11c
 
 
 
 DCs from the mediastinal lymph nodes of infected mice selectively stimulated
both OVA- and influenza-specific T cells and underwent maturation, with higher levels of
MHC class II, CD80, and CD86 molecules. The relatively slow (2–3 d) kinetics of maturation
correlated closely to the time at which OVA inhalation elicited specific antibodies. Therefore
respiratory infection can induce DC maturation and simultaneously B and T cell immunity to
an innocuous antigen inhaled concurrently.
Key words: inﬂuenza virus • dendritic cell • maturation • endotoxin free ovalbumin • airway
 
Introduction
 
The respiratory portal serves as an important entry site for
pathogenic organisms, but it is also a site for effective innate
and adaptive immune responses. An important constituent
of the airways are antigen presenting DCs, which line the
alveolar septae and airway epithelia (1–4) and are capable of
capturing and presenting antigens to initiate immunity es-
pecially within the draining mediastinal or peribronchial
lymph nodes (5–9). This defense mechanism imposes a risk
however, which is that the respiratory tract also is chroni-
cally exposed to many innocuous but potentially immuno-
genic proteins. In fact, DCs appear to be capturing proteins
from the airway constitutively (6, 8). As DCs may capture
these harmless proteins together with a pathogen, there also
is a potential for the development of unwanted immune re-
sponses and chronic reactivity to airway proteins (10). Can
the DC arm of the immune system avoid the capture of
harmless airway proteins during an infection?
We set out to investigate this question using OVA, as a
model harmless protein, and influenza virus as a common
respiratory pathogen. In planning the experiments, we
considered the fact that the initiation of T cell–mediated
immunity entails two broad groups of changes in antigen
presenting DCs: the capture and successful processing of
antigens to form MHC–peptide complexes, the ligands for
T cell antigen receptors, and the maturation of the DCs to
acquire costimulatory and other functions required for the
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induction of immunity (11–13). Influenza virus is associ-
ated with the maturation of DCs in tissue culture (14–16)
and recently in vivo (17).
A number of prior studies have shown that respiratory
virus infections can enhance the immune response to pro-
tein antigens (18–25). However, in an effort to establish an
allergy model, many of these prior investigations used alum
as an adjuvant to polarize the immune response toward the
Th2 type that is associated with allergy. Another compli-
cating feature was that the antigens used in prior studies
were from sources that are now known to be contaminated
with LPS. Eisenbarth et al. (26) recently reported on the
immune response to intranasal OVA in the presence of low
(0.1 
 
 
 
g) or high (100 
 
 
 
g) levels of LPS. They found anti-
body and T cell responses in both instances, but that the
high dose of LPS converted these responses from a Th2 to
a Th1 type. Akbari et al. (27) also followed the immune re-
sponse to OVA applied intranasally. They noted a strong
up-regulation of costimulatory molecules on the DCs in
the draining lymph node, and that these DCs could elicit
IL-10–producing regulatory T cells. The observed up-reg-
ulation of costimulatory molecules signifies that the OVA
administration was somehow accompanied by a DC matu-
ration stimulus. Therefore, it seemed important to use en-
dotoxin free antigens to assess if immunity will develop to a
harmless airway protein given before, or concurrently with,
an influenza infection.
Here we show that endotoxin free preparations of OVA
do not immunize either the B or T cell compartments
when inhaled, and that the OVA is tolerogenic. Never-
theless, the OVA is presented efficiently by DCs in the
mediastinal lymph nodes in the steady-state, at substantial
levels to what is observed when OVA is given during an
influenza virus infection. However, only in the latter in-
stance do the mice develop antibodies as well as combined
Th1 type CD4
 
 
 
 and CD8
 
 
 
 T cell immunity to OVA. We
find that influenza virus infection of the respiratory tract,
but not OVA alone, induces maturation of DCs in the
draining mediastinal lymph nodes; this maturation corre-
lates with the induction of immunity to the otherwise
harmless protein OVA in the airway. These results empha-
size that the mucosal immune system must have efficient
tolerance mechanisms to avoid simultaneous immuniza-
tion to resident foreign proteins that are later processed by
DCs during infection.
 
Materials and Methods
 
Mice.
 
C57BL/6 (B6) female mice were purchased from
Taconic and used at 8–12 wk of age. OT-I mice were provided
by Dr. F. Carbone (University of Melbourne, Parkville, Victoria,
Australia), and OT-II mice were obtained from the Trudeau In-
stitute. CD45.1
 
 
 
 OT-I mice were produced by crossing OT-I
with B6.SJL-Ptprc mice.
 
Antibodies.
 
Antibodies to CD80/16–10A1, CD86/GL1, MHC
class II I-A
 
b
 
/AF6–120.1, B220, and CD45.1/A20 were pur-
chased from BD Biosciences. Hybridomas producing antibodies
were obtained from the American Type Culture Collection
 
including MHC class II (M5/114, TIB120), F4/80 (HB 198),
NK1.1, B220 (RA3–6B2), CD4 (GK1.5, TIB 207), and CD8
(53.6.7, TIB 105).
 
Viruses.
 
Influenza virus A/HK X-31 (X-31), H3N2 subtype
and B/Lee/40 were grown for 40 h in 9 d embryonated eggs at
37
 
 
 
C. Allantoic fluid was harvested and stored at 
 
 
 
80
 
 
 
C. Virus
stocks and virus-infected lungs were titrated by infection of Ma-
din-Darby Canine Kidney cells (MDCK) as described elsewhere
(28). Vaccinia-OVA virus was grown for 48h in CV-1 cells (kid-
ney cells from African green monkey) in DMEM, 10% FCS at
37
 
 
 
C. The CV-1 cells containing the vaccinia-OVA virus were
harvested and stored at 
 
 
 
80
 
 
 
C. CV-1 cells were infected to titer
virus stocks and lung extracts. CV1 cells were seeded at 3 
 
 
 
 10
 
5
 
/ml
in 96-well plates and when confluent, they were incubated with
serial dilutions (25 
 
 
 
l) of virus stocks or lung extract for 1 h. Ex-
tra media was added and the plates incubated for 48 h at 37
 
 
 
C.
The supernatant was discarded, the plates were stained with crys-
tal violet solution, and plaque forming units were counted.
 
Infection of Mice with Influenza and Vaccinia Viruses.
 
Infections
of mice with influenza A (X-31) and B (B/Lee) were performed
in an infection chamber. For X-31 a 1:50 dilution of virus (10
 
6.9
 
TCID
 
50
 
/25 
 
 
 
l allantoic fluid) in sterile PBS was used. This infec-
tion resulted in the following lung virus titers expressed as
TCID
 
50
 
/25 
 
 
 
l of lung extract: 20 h after infection, 10
 
3.91 
 
 
 
 0.47
 
; 45 h
after infection, 10
 
6.3 
 
 
 
 0.41
 
; 72 h after infection, 10
 
6.4 
 
 
 
 0.48
 
; 96 h
after infection, 10
 
6.4 
 
 
 
 0.33
 
; 7 d after infection, 10
 
5.1 
 
 
 
 0.35
 
; and 10 d
post infection, below detection. For B/Lee a 1:20 dilution of vi-
rus (2 
 
 
 
 10
 
7
 
 pfu/ml allantoic fluid) in sterile PBS was used. 7 ml
virus solution was nebulized into the chamber resulting in infec-
tion of 100% of the mice. For infection with recombinant vac-
cinia OVA virus, mice were anaesthetized with avertin (Sigma-
Aldrich) and inoculated with 10
 
5
 
 pfu intranasally.
 
Administration of OVA and Measurement of Endotoxin Levels.
 
Administration of OVA was performed in an infection chamber.
The mice were exposed for 15 min to a solution of 10 mg/ml egg
white OVA (Charles River Laboratories) or commercial OVA
(Calbiochem-Novabiochem) dissolved in sterile PBS. A control
group receiving aerosolized PBS was always included in every ex-
periment. For determination of endotoxin levels in the OVA
preparations, the Limulus amebocyte Lysate assay (Biowhittaker
Inc.) was used according to the manufacturer’s protocol.
 
Detection of DC Maturation In Vivo.
 
X-31 virus or OVA was
administered by aerosol into the airway as above. The draining
lymph nodes were harvested at 20 h to 10 d after infection, and
CD11c
 
 
 
 cells were isolated by staining with PE conjugated anti-
CD11c (BD Biosciences) and anti-PE microbeads (Miltenyi Bio-
tec) as described in the manufacturer’s protocol. The CD11c
 
 
 
 or
CD11c
 
 
 
 cells were stained with FITC-labeled antibodies against
F4/80 (Serotec), CD80, CD86, I-A
 
b
 
 (BD Biosciences), APC-
labeled antibody against B220 (BD Biosciences), and PerCP-
labeled antibody against CD11b (BD Biosciences) and were ana-
lyzed by flow cytometry (FACSCalibur™; BD Biosciences).
 
Purification and Proliferation of OT-I and OT-II, OVA-specific,
TCR Transgenic T Cells.
 
To purify OT-I and OT-II T cells, as
described elsewhere (29), spleen and lymph nodes were harvested
and the single cell suspension incubated with hybridoma superna-
tants directed against MHC II, F4/80, B220, NK1.1 and CD4 or
CD8 (depletion) and goat anti-rat Dynabeads (Dynal) to enrich
for CD8
 
 
 
 or CD4
 
 
 
 T cells, respectively. For analysis of in vivo
proliferation, the enriched OT-I and OT-II T cells were labeled
with CFSE. In brief, 10
 
7
 
 cells/ml were incubated with CFSE
(Molecular Probes) at 5 
 
 
 
M for 10 min at 37
 
 
 
C. An equal vol-
ume of FCS was added, and the cells were washed twice in PBS,T
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0.1% BSA, and once with PBS before intravenous injection of
2–3 
 
 
 
 10
 
6
 
 CFSE-labeled OT-I or OT-II T cells into B6 mice.
The following day, the mice were infected with X-31 or PBS and
then administered egg OVA for 3 consecutive days. 5 (OT-II) or
6 d (OT-I) after infection with X-31, the draining lymph nodes
were harvested and stained for expression of CD45.1 and CD8 or
CD4. The proliferation of OT-I and OT-II T cells was analyzed
by flow cytometry.
 
In Vitro Proliferation Assay for OVA and Influenza Presentation.
 
B6 mice were infected with X-31 or given PBS as a control on
day 1. On days 2, 3, and 4, they were administered egg OVA and
on day 5 the draining lymph nodes were harvested and incubated
with 1 mg/ml collagenase D (Roche) for 25 min at 37
 
 
 
C.
CD11c
 
 
 
 cells were purified as above. The CD11c
 
 
 
 fraction was
further depleted for T cells using anti-CD5 beads (Miltenyi Bio-
tec) according to the manufacturers protocol. Graded doses of
CD11c
 
 
 
 or CD11c
 
 
 
 cells were cultured at 37
 
 
 
C with 10
 
5
 
 OT-I
or OT-II T cells in round bottom 96-well plates, to which 
 
3
 
H-
thymidine (1 
 
 
 
Ci/well; Amersham Biosciences) was added at 48–
72 h to detect incorporation into DNA. For evaluation of influ-
enza peptide presentation by CD11c
 
 
 
 cells, B6 mice were in-
fected with X-31 on day 1 and on day 12 bulk T cells were puri-
fied from the draining LNs and used as responder cells in a
proliferation assay. In brief the LN cells were depleted from B
cells, DCs, and macrophages by using anti-CD19, anti-CD11c,
and anti-MHC class II microbeads (Miltenyi Biotec) according to
the manufacturers protocol. For generation of APCs B6 mice
were infected with X-31 or mock infected on day 1, and on day
5 CD11c
 
 
 
 and CD11c
 
 
 
 cells were isolated from the draining LNs
and cocultured with 10
 
5
 
 bulk T cells from influenza virus infected
animals to assess the T cell proliferative response.
 
Intracellular Cytokine Production from OT-I and OT-II T Cells.
 
B6 mice were injected with 10
 
6
 
 OT-I or OT-II T cells intrave-
nously. After aerosol administration of OVA with or without
concomitant influenza infection as above, draining mediastinal
lymph nodes were harvested at day 6 and 5 
 
 
 
 10
 
6
 
 cells were cul-
tured for 5 h in 24-well plates with OVA
 
257–264
 
 (OT-I) or
OVA
 
323–339
 
 (OT-II) in the presence of 10 
 
 
 
g/ml Brefeldin A
(Sigma-Aldrich). After harvesting the cells were stained for ex-
pression of CD45.1, CD4/CD8, and intracellular IL-2 or IFN-
 
 
 
.
For intracellular cytokine staining, the PharMingen Cytokine
Staining Starter Kit was used. The expression of cytokines was
evaluated by flow cytometry.
 
Detection of OVA-specific Antibodies.
 
X-31 influenza virus was
used to infect B6 mice on day 1 and then egg OVA was aero-
solized on days 2, 3, and 4 as above. 14 d after infection, the mice
were bled and serum levels of OVA-specific antibodies deter-
mined by ELISA. Briefly, the plates were coated with 5 
 
 
 
g/ml
OVA overnight and blocked with PBS plus 1% BSA. 10-fold se-
rum dilutions were incubated for 2 h at room temperature. The
plates were washed, incubated with peroxidase conjugated anti–
mouse IgG1 or IgG2b for 1 h (Boehringer), washed, and bound
antibodies detected by adding ABTS tablets (Boehringer). The
OD was measured at 405 nm. For OVA-specific IgE detection,
plates were coated overnight with 2.5 
 
 
 
g/ml rat anti–mouse IgE
(BD Biosciences) followed by 10-fold serum dilutions for 2 h at
room temperature. After washing, the plates were incubated with
5 
 
 
 
g/ml biotinylated OVA for 2 h, washed and incubated with
streptavidin-POD (Roche Diagnostic Corporation) for 1 h. The
plates were developed as above.
 
Cytotoxicity Assay.
 
B6 mice were infected with X-31 on day
1 and followed by OVA on days 2, 3, and 4. 8 d after infection,
the mediastinal lymph nodes were harvested and 20 
 
 
 
 10
 
6
 
 lymph
 
node cells were stimulated in vitro with 20 
 
 
 
 10
 
6
 
 spleen cells
from naive B6 mice for 5 d at 37
 
 
 
C, 7% CO
 
2
 
. The spleen cells
had been gamma irradiated and pulsed with SIINFEKL peptide
(5 
 
 
 
g/ml final concentration) for 1 h at 37
 
 
 
C followed by wash-
ing to remove excess peptide. The cytotoxicity assay was per-
formed as described elsewhere (30). Briefly cells from the 5 d cul-
tures were mixed with 
 
51
 
Cr-labeled EL-4 target cells in V bottom
96-well plates. The target cells were prepared by pulsing 2 
 
 
 
 10
 
6
 
EL-4 cells with SIINFEKL peptide (5 
 
 
 
g/ml final concentration)
or PBS for 1 h at 37
 
 
 
C and then labeled with 100 
 
 
 
Ci sodium
chromate (Dupont/New Life Science Products) for 1 h. Effector
cells were added at various effector/target ratios and incubated
4 h at 37
 
 
 
C. The supernatants were harvested and released radioac-
tivity was measured in a gamma-counter. Percent cytotoxicity
was calculated using the formula: % cytotoxicity 
 
 
 
 (test release –
spontaneous release)/(maximum release – spontaneous release) 
 
 
 
100. Maximum and spontaneous release was determined by incu-
bating the cells with 0.5% NP-40 or media, respectively.
 
Statistical Analysis.
 
The Mann-Whitney test was used for data
analysis.
 
Results
 
Identification of Endotoxin-free OVA That Is Nonimmuno-
genic via the Airway.
 
To identify an abundant source of an
endotoxin free and harmless protein antigen, we used egg
white as a source of OVA. We compared the endotoxin
levels in egg white OVA and commercially available OVA
using the Limulus Amebocyte Lysate assay. The egg white
OVA was endotoxin free (below detection level 
 
 
 
0.1
EU/ml) at a concentration as high as 10 mg/ml OVA. In
contrast, the commercial source of OVA was contami-
nated with endotoxin, as 100 
 
 
 
g/ml OVA contained 2
EU/ml. When administered to B6 (Fig. 1) or BALB/C
(unpublished data) mice via the airway, the commercial
“LPS OVA” induced anti-OVA antibody responses pri-
marily of the IgG1 and IgG2b isotypes, whereas the LPS-
free “egg OVA” did not induce antibodies (Fig. 1, A and
B). To assess the response to the two different forms of
OVA at the T cell level, we measured the generation of
CD8
 
 
 
 CTL, but neither preparation of OVA was immu-
nogenic (Fig. 1 C). We therefore prioritized the use of egg
OVA as a harmless protein that is by itself nonimmuno-
genic via the airway.
 
Coadministration of OVA and Influenza Virus Leads to
OVA-specific Antibodies and CTLs.
 
To assess the effect of
influenza virus infection on immune responses to OVA,
B6 mice were infected with influenza virus or mock in-
fected with PBS at day 1, and then either LPS OVA or
egg OVA was administered by aerosol on three consecu-
tive days, days 2, 3, and 4. 14 d after infection, the serum
was analyzed for OVA-specific antibodies. Mice that re-
ceived influenza virus and egg OVA now produced
OVA-specific, IgG1 and IgG2b antibodies, while mice
that received egg OVA alone did not (Fig. 1 A). We also
detected small levels of OVA specific IgE in mice infected
with influenza virus and administered LPS OVA, while
mice administered influenza virus followed by LPS-free
egg OVA failed to produce these antibodies (Fig. 1, A andT
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B). To examine whether a cellular immune response was
generated, we measured the OVA specific CTL response.
B6 mice were treated as described above and 8 d after in-
fluenza virus infection the mediastinal lymph node cells
were isolated and restimulated with the SIINFEKL pep-
tide for 5 d in vitro. In mice that received influenza virus
and egg OVA, OVA-specific CTLs were induced, while
none of the control groups demonstrated any CTL activ-
ity (Fig. 1 C). Also, we were able to detect an effect of en-
dotoxin in the commercial OVA, because the CTL re-
sponse initiated using LPS OVA and virus infection was
stronger than when egg OVA was used (Fig. 1 C). These
results demonstrate that endotoxin-free OVA adminis-
tered by aerosol into the respiratory tract fails to prime for
an immune response, but if given during an influenza vi-
rus infection, OVA-specific humoral and cellular immune
responses are generated.
 
LPS-free OVA Given before Infection Is Able to Induce Toler-
ance.
 
While LPS-free OVA was nonimmunogenic, the
prior studies did not differentiate between immune igno-
rance or active immune tolerance as the underlying mecha-
nism. To begin to examine this, we gave mice soluble egg
OVA for 3 d by the airway, infected with influenza virus,
and then followed by further doses of soluble LPS OVA as
in the prior immunizing regimen of Fig. 1 C. The mice
pretreated with soluble LPS-free OVA (Fig. 1 D, the group
labeled egg OVA, then influenza 
 
 
 
 LPS OVA) now failed
to develop CTLs in response to coadministered LPS-OVA.
The tolerance was specific in that CTL responses to influ-
enza developed comparably to those seen in mice that had
Figure 1. Generation of antibody and CTL responses in naive animals following coadministration of OVA and influenza virus. (A and B) B6 mice
were infected with aerosolized X-31 on day 1 followed by egg OVA (A) or LPS OVA (B) on days 2, 3, and 4. 14 d after infection, serum levels of
OVA-specific antibodies were determined by ELISA (mean   SD from four individual mice; representative of two or more experiments. (C) B6 mice
were infected with aerosolized X-31 on day 1 and given LPS OVA or egg OVA on days 2, 3, and 4. 8 d after infection the mediastinal lymph nodes
were harvested and the lymph node cells were restimulated with SIINFEKL in vitro for 5 d. Data are means   SD from groups of four mice and repre-
sentative of three experiments. (D) B6 mice were given egg OVA on days –5,  3, and –1. On day 1, the mice were infected with X-31 and on days 2,
3, and 4 they were administered LPS OVA (egg OVA, then influenza   LPS OVA). A positive control group which was infected with X-31 on day 1
and administered LPS OVA on day 2, 3, and 4 was also included (influenza   LPS OVA). Data are means   SD from groups of four mice and represen-
tative of two experiments.T
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not received OVA (unpublished data). Therefore while
coadministration of a harmless protein with influenza leads
to immunity, prior administration of that harmless protein
is capable of inducing tolerance.
Airway OVA Is Presented in the Draining Lymph Nodes in
the Steady State. To investigate whether the lack of im-
mune response toward endotoxin-free OVA, when admin-
istered in the absence of influenza virus infection, stemmed
from a failure of OVA to reach the draining lymph nodes,
we took advantage of transgenic CD8  OT-I T cells (rec-
ognizing OVA257–264 [SIINFEKL] on Kb) and CD4  OT-II
T cells (recognizing OVA323–339 on Ab) to report on the
presentation of MHC–peptide in the lymph nodes. These
T cells were labeled with CFSE and infused into naive B6
mice. The mice then received influenza virus (day 1) and
egg OVA (days 2, 3, 4), or the mice were mock infected
(day 1) and given egg OVA (days 2, 3, 4). On day 6, we
monitored T cell proliferation in the draining (mediastinal)
and distal (cervical) lymph nodes by flow cytometry, look-
ing for a progressive halving of the CFSE labeling per cell
as an index of T cell proliferation and successful OVA pre-
sentation. As shown in Fig. 2, both OT-I and OT-II T
cells proliferated in the mediastinal lymph nodes (Fig. 2 A),
and to a much lower extent in the cervical nodes (Fig. 2 B),
demonstrating that OVA was presented locally on both
MHC class I and II products in the lymph nodes draining
the airways. Interestingly, we observed comparable prolif-
eration of transgenic T cells in mice receiving influenza vi-
rus and egg OVA, as well as mice that only received egg
OVA. Thus, the OVA antigen was indeed transported to
the draining LNs and presented as MHC–peptide com-
plexes, both in the presence and absence of virus infection.
We did not further assess if the OVA was transported by
migrating DCs or if OVA was gaining direct access via the
lymph to the DCs in the draining lymph node.
Coinfection with Influenza Virus Leads to OVA-specific, Ef-
fector T Cell Formation. As we observed comparable pro-
liferation of OT-I and OT-II T cells in mice given aerosol
OVA without or with influenza virus (Fig. 2), we were in-
terested in determining the differentiation of these T cells
into effector cells in vivo. Mice were given the transgenic
T cells at day 0, influenza or mock infected at day 1, and
then given 3 doses of egg OVA on days 2, 3, and 4. On day
6, the lymph node cells were isolated, and stimulated 5 h
with OVA peptides appropriate for the antigen presenting
H-2Kb and I-Ab molecules. T cells were then studied by
flow cytometry to monitor T cell numbers as well as the
intracellular accumulation of IL-2 and IFN- . Administra-
tion of egg OVA, with or without influenza virus infec-
tion, expanded the numbers of T cells as expected from the
prior CFSE experiments (Fig. 2), although the expansion in
T cell numbers at day 6 was threefold higher if there was
influenza coinfection (Fig. 3, A and B, top rows). More
dramatic differences were noted at the level of cytokine
production, as much higher proportions of OT-I and OT-II
T cells producing IL-2 and IFN-  were detected when
mice were aerosolized with influenza virus and egg OVA,
and virtually no cytokine production was seen in the ab-
sence of influenza virus (Fig. 3, A and B, middle and lower
rows). OVA-specific, transgenic T cells from mice treated
only with influenza virus or PBS did not produce signifi-
cant cytokines, i.e., little IL-2 or IFN-  was detected (Fig.
3) and no IL-4 or IL-10 (unpublished data). Therefore in-
fluenza virus infection has a striking effect on the functional
outcome of the OVA specific T cell response, leading to
IL-2 and IFN-  production.
CD11c  DCs Present OVA and Viral Antigens in the
Draining Lymph Nodes. To define the cell types involved
in the presentation of OVA in the draining lymph nodes,
we purified CD11c  and CD11c  cells and added these to
cultures of OVA-specific transgenic T cells to stimulate
proliferation. Again, the mice received either aerosolized
influenza virus or mock infection, followed by aerosolized
egg OVA for three consecutive days. 1 d after the last OVA
treatment, the antigen-presenting cells were purified from
draining mediastinal lymph nodes and nondraining brachial
Figure 2. Active presentation of airway
OVA in the draining mediastinal lymph
nodes in the presence or absence of influ-
enza virus infection. 2–3   106 CFSE-labeled
OT-I or OT-II T cells were injected intra-
venously into B6 mice at day 0. On day 1
the mice were infected with X-31 or mock
infected and then administered egg OVA
on day 2, 3, and 4. 5 (OT-II) or 6 d (OT-I)
after infection with X-31 the draining LNs
were harvested and stained for expression of
CD45.1 and CD8/CD4. Shown is prolifer-
ation of OT-I and OT-II T cells in the
draining mediastinal with and without egg
OVA in the presence and absence of influ-
enza virus (A) and nondraining cervical in
the presence of egg OVA (B) lymph nodes.
Data are representative of three experi-
ments.T
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lymph nodes and tested (Fig. 4). Only CD11c  cells from
the mediastinal lymph nodes could elicit OT-I T cell pro-
liferation, indicating that DCs were the major cell involved
in the presentation of OVA in the draining lymph nodes.
CD11c  cells from mice infected with influenza virus and
egg OVA were much more efficient at presenting OVA to
OT-I (and OT-II cells, unpublished data) than CD11c 
cells from mice receiving egg OVA only (Fig. 4 A), but the
later did stimulate above the PBS background control. The
DCs from influenza virus infected mice also stimulated in-
fluenza primed T cells (Fig. 4 B), demonstrating that DCs
as a population are capable of both presenting OVA pep-
tides and influenza virus peptides.
Influenza Virus Induces Maturation of DCs In Vivo. Be-
cause influenza infection was associated with an immune
response to coadministered OVA, we looked for the devel-
opment of mature DCs in the mediastinal lymph nodes, us-
ing changes in cell surface phenotype as a criterion. Mice
inhaled aerosolized OVA or influenza, and then we evalu-
ated the expression of maturation markers on CD11c  and
CD11c  cells 72 h later. The expression of CD80, CD86,
and MHC II were each up-regulated on CD11c  cells
from influenza virus–infected animals, when compared
with cells from mice that were mock infected or received
egg OVA only (Fig. 5). As Akbari et al. (9) recently de-
scribed the induction of ICOS-L as well as CD80 and
CD86 after intranasal OVA, we also checked for expression
of ICOS-L on mediastinal lymph node DCs 3 d after inha-
lation of LPS-free OVA. While CD80 and CD86 expres-
sion increased markedly after influenza virus infection,
ICOS-L was only slightly up-regulated and only in the
presence of influenza virus (unpublished data). The influ-
enza virus infection also had an impact on the number of
CD11c  cells in the draining lymph nodes, because the fre-
quency of CD11c  cells and the total number of mediasti-
nal lymph node cells were each increased up to twofold
compared with mock infected mice or mice administered
egg OVA. Influenza infection also was accompanied by an
expansion of CD11c  CD11b  macrophages expressing or
not expressing the F4/80 antigen (Fig. 5 C, arrows), but in
contrast to DCs, B cells and macrophages did not show in-
creased expression of CD80/86 (Figs. 5, B and D). Overall
these results demonstrate that influenza virus leads to DC
maturation without inducing T cell costimulatory mole-
cules on B cells and macrophages.
The Maturation Status of the DCs Correlates with the Ability
to Induce Production of OVA-specific Antibodies. To test if the
maturation status of the DCs was correlated with the
priming of OVA-specific immunity, we first assessed matu-
ration at several time points after influenza virus infection.
20 h after infection, we did not observe any differences in
the levels of costimulatory molecules (CD80 and CD86)
and MHC II between influenza virus and mock-infected
mice. However, by 45 h we detected an up-regulation of
CD80, CD86, and MHC II in mice infected with influ-
enza virus, and this effect was maximal at 72 h (Fig. 6 A).
At 96 h, the expression of maturation markers was slightly
reduced compared with the 72 h time point. At day 7, we
observed a down-regulation of maturation markers com-
pared with the mock-infected mice, and this down-regula-
tion was even more pronounced at day 10 (unpublished
data). At the same time points during the course of influ-
Figure 3. Coadministration of OVA and influenza virus leads to formation of OVA specific cytokine producing effector cells. B6 mice were injected
with 106 OT-I or OT-II T cells intravenously on day 0. Day 1 mice were infected with X-31 or mock infected and administered egg OVA on day 2, 3,
and 4. On day 6 the draining lymph nodes were harvested and 5   106 cells were cultured for 5 h with SIINFEKL (OT-I) or OVA323–339 (OT-II) in the
presence of Brefeldin A. After harvesting, the cells were stained for expression of CD45.1 and CD4/CD8 and intracellular IL-2 or IFN- . The response
of OT-II T cells (A) and OT-I T cells (B) is shown for cell numbers (top rows) and IFN- /IL-2 production (middle and lower rows) in the mediastinal
LNs. Data are representative of two experiments.T
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enza infection (0, 20, 45, 72, 96 h, 7 d, 10 d), we aero-
solized a single dose of egg OVA and evaluated the OVA-
specific antibody response as a read-out for immune prim-
ing. As shown in Fig. 6 B, the production of OVA-specific
antibodies correlated with the degree of maturation of the
DCs. The best responses were obtained when the matura-
tion of the DCs was peaking, whereas negligible OVA-spe-
cific antibody responses were induced when OVA was
given at 0, 20 h, or days 7 and 10. These results indicate
that the maturation of DCs in vivo correlates well with the
induction of immune responses.
OVA-specific T Cell Immunity Is Associated with Protection
against Vaccinia OVA Infection. To test if the strong T cell
responses to OVA in influenza infected mice also led to
OVA-specific resistance to infection, a different recombi-
nant OVA virus was used. A vaccinia virus carrying the full
length OVA gene has been shown to present OVA-derived
peptides on the surface of infected cells. We infected B6
mice with influenza virus and administered egg OVA on
day 2, 3, and 4, then rested the mice for 3 wk before boost-
ing with influenza B virus and 3 doses of egg OVA. Influ-
enza B virus infects mice with similar kinetics to influenza
A virus, but neither T cells nor antibodies elicited to influ-
enza A cross react with the influenza B used to boost OVA
immunity. The boost with a second heterologous virus was
needed to induce significant protection to vaccinia-OVA
challenge. 3 wk after the second boost, the mice were chal-
lenged with vaccinia-OVA intranasally. 7 d after infection
the lungs were harvested and virus particles in the lungs
were evaluated to assess the level of protection imparted by
the OVA-specific T cell response.
As shown in Fig. 7 A, mice treated with both influenza
and egg OVA had a significantly lower vaccinia virus titer
compared with all the control groups. The influenza
group, the most important control group, had 7 times
higher vaccinia titers than influenza egg OVA groups,
while the two other control groups had 40–60 times
higher virus titers. Losses of body weight, as a manifesta-
tion of influenza infection, were also monitored (Fig. 7 B).
The weight loss data correlated with the virus titers in the
lungs, i.e., there was much less weight loss in protected an-
imals with lower virus titers. We also assayed the produc-
tion of IFN-  from CD8  T cells in the spleens of OVA-
vaccinia challenged mice and found that mice administered
Figure 4. Presentation of OVA and viral antigens by DCs from the draining mediastinal lymph nodes. B6 mice were infected with X-31 or mock in-
fected on day 1. On day 2, 3, and 4, they were administered egg OVA. On day 4, CD11c  and CD11c  cells were purified from the draining LNs (six
mice/group) and cocultured with OT-I cells for 48–72 h and assessed for T cell proliferation by 3H-thymidine incorporation. (A) Proliferation of OT-I
T cells in the presence of CD11c  or CD11c  lymph node presenting cells purified from draining mediastinal lymph nodes and nondraining brachial
lymph nodes. (B) Proliferation of bulk influenza virus-specific T cells in the presence of CD11c  and CD11c  cells enriched from the draining lymph
nodes in part A.T
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egg OVA in the presence of influenza virus had a higher
proportion of IFN-  producing CD8  T cells when re-
stimulated with the OT-I peptide (SIINFEKL) relative to
the other experimental groups (Fig. 7 C). In the same mice
we analyzed the OVA specific antibody response after ad-
ministration of egg OVA to follow the priming of the
mice. As shown in Fig. 7 D, the level of OVA-specific an-
tibodies increased from the first immunization to the sec-
ond OVA exposure, and after challenge with vaccinia–
OVA, antibody levels were further enhanced. Importantly,
there was no demonstrable OVA-specific antibodies in
mice administered egg OVA only, even after exposure to
OVA seven times over a 7-wk period. These mice failed to
make any detectable level of antibody, emphasizing that
endotoxin free OVA is not immunogenic via the airway
but induces protective OVA-specific immunity if inhaled
during an influenza infection.
Discussion
The Interaction of a Nonimmunogenic Airway Protein with
DCs in the Steady-State. The immature DCs within lym-
phoid organs are able to capture antigens by a variety of
routes, e.g., as solutes in the fluid phase or bound to uptake
receptors (29, 31, 32) and as particles during phagocytosis
(33–35). Uptake can take place without ostensible pertur-
bation of DC markers and function. Following uptake, the
antigens are presented to T cells, but the T cells are not im-
munized, failing to develop effector functions and memory
(29, 31, 33). In this paper, we have monitored the response
of DCs and the immune system to inhalation of an endo-
toxin-free preparation of OVA. We first noted that our
preparations of OVA were nonimmunogenic at the level of
B and T cell responses (Fig. 1, A and C). In most prior
studies, even those concluding that OVA could introduce
tolerance after intranasal application (36), priming for IgG
but not IgE antibody responses was observed. Nevertheless,
DCs in the mediastinal lymph nodes that drain the lower
airway, but not the cervical nodes that drain the upper air-
Figure 5. Influenza virus induces maturation of DCs from the draining
mediastinal lymph nodes. Six B6 mice/group were administered X-31,
PBS, or egg OVA at time point 0. The egg OVA group received OVA at
24 and 48 h also. 72 h after infection CD11c  and CD11c  cells were
purified from the draining lymph nodes and stained for expression of
CD80, CD86, MHC II, B220, CD11b, and F4/80. (A) The DC popula-
tion is gated on CD11c  cells, (B) the B cell population is gated on
B220  cells and (C and D) the macrophages are gated as CD11c ,
CD11b , and F4/80  or F4/80  (arrows to the two macrophage subsets).
Data are representative of at least two experiments.
Figure 6. Influenza virus induced DCs maturation correlates with pro-
duction of OVA-specific antibodies. (A) Six B6 mice/group were in-
fected with X-31 or mock infected and CD11c  cells were purified from
the draining LNs 20, 45 and 72 h after infection and stained for expres-
sion of CD80, CD86, and MHC II. (B) Four mice/group were infected
with X-31 at time point 0. At various time points post virus infection (0,
20, 45, 72, 96 h, 7 d, and 10 d), the mice received a single dose of egg
OVA. 22 d after virus infection, the serum was analyzed for OVA-specific
IgG1 and IgG2b antibodies. All the black bars are significantly different
from the white bars (P   0.05) except for day 7 in the IgG1 chart. Data
are expressed as mean   SD and shown at 1:10 serum dilutions. Data are
representative of three experiments.T
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way, acquire and present LPS-free OVA on MHC class I
and II products. The mediastinal (peribronchial) lymph
node DCs otherwise were not perturbed relative to un-
treated mice with respect to several cell markers that char-
acteristically increase during inflammation and infection,
e.g., CD40, CD80, CD86, ICOS-L, and MHC class II
(Fig. 5). This finding is also different from prior reports in
which intranasal application of OVA led to marked in-
creases in the expression of these molecules (9). Impor-
tantly, the immunologic outcome for T cells in both in-
stances can be tolerance to OVA. In the seminal studies of
Akbari et al. (27), the administration of OVA led to the in-
duction of regulatory T cells that could produce high levels
of IL-10 and suppress OVA-specific CD4  T cell reactiv-
ity. In our studies with endotoxin free OVA, we did not
detect IL-10 in responding T cells, but we did observe tol-
erance (Fig. 1 D). However, we did not investigate the un-
derlying mechanism, e.g., to assess whether tolerance might
involve peripheral T cell deletion, as has been observed
with DCs presenting other antigens in the steady-state (29,
31, 33), anergy, or regulatory T cell induction. Neverthe-
less, our studies show that immature DCs in lymph nodes
need not ignore nonimmunogenic proteins in the airway
and can efficiently present these as MHC–peptide com-
plexes in the obstensible absence of DC maturation, and B
and T cell priming.
The Response to Endotoxin-free OVA When Inhaled during
the Course of Airway Infection with Influenza Virus. When
DCs in lymphoid tissues are exposed in vivo to defined
maturation stimuli, such as LPS (37), CpG deoxyoligonu-
cleotides (38), NKT cells (39) and CD40 agonists (29, 31,
33), the DCs markedly up-regulate the expression of T cell
costimulatory molecules and become effective inducers of
immunity. In this paper, we find that DCs in the draining
lymph nodes selectively undergo maturation over a period
of 2–3 d after inhalation of influenza (Figs. 5 and 6 A).
These kinetics are much slower than a recent report of
maturation within 6 h of administration of influenza (17).
We do not understand the basis for this difference in kinet-
ics, since in our hands, influenza titres expand considerably
between day 2 and 3, when the maturation of DCs be-
comes evident. In any case, when OVA was aerosolized af-
ter the onset of influenza infection, immunogenicity was
observed simultaneous with the presence of maturing DCs,
i.e., when the OVA was inhaled 2–3 d after the administra-
tion of influenza. The response to OVA in the presence of
influenza virus coinfection was primarily of the Th1 type,
based on the generation of IgG2a (BALB/c unpublished
data) or IgG2b (B6) but no IgE antibodies, and the expan-
sion of IFN-  secreting CD4  and CD8  T cells, as well as
lytic CD8  T cells. Animals immunized with OVA during
a virus infection also had improved recovery to a subse-
Figure 7. Generation of pro-
tective immunity following coad-
ministration of OVA and influ-
enza virus. B6 mice were infected
with aerosolized X-31 on day 1
and administered egg OVA on
day 2, 3, and 4. 3 wk after infec-
tion the groups that received
X-31 (influenza   egg OVA and
influenza) were infected with B/
Lee and boosted with egg OVA
for three consecutive days (only
influenza   egg OVA and egg
OVA groups). 3 wk after infec-
tion with B/Lee all the groups
were challenged with 105 pfu/
mouse Vaccinia-OVA intranasally.
7 d after vaccinia-OVA infection
the lungs were harvested and an-
alyzed for virus and the spleen
was assayed for IFN- –produc-
ing T cells. Also, the serum was
collected after each administra-
tion of egg OVA to measure
production of OVA specific an-
tibodies. (A) Vaccinia virus titer
in lungs. Data are expressed as
mean   SD from groups of five
mice. The difference between
the influenza   egg OVA and
the influenza group was statisti-
cally significant (*P   0.05). Data are representative of four independent experiments. (B) Weight loss in mice infected with vaccinia–OVA. (C) Produc-
tion of IFN-  from CD8 T cells from spleen cells restimulated with SIINFEKL. Data are representative of two independent experiments. (D) OVA spe-
cific IgG1 antibody production after primary immunization (influenza A   egg OVA), secondary immunization (influenza B   egg OVA), and tertiary
immunization (vaccinia-OVA). Antibodies (IgG1 and IgG2b [unpublished data]) were observed only in the serum of animals given OVA and virus infec-
tion. The results shown are 1:100 serum dilutions but identical results were observed with a 1:10 dilution. Data are expressed as mean   SD from groups
of five mice.T
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quent challenge with a recombinant vaccinia virus express-
ing full length OVA.
Prior studies in which OVA was coadministered with
influenza virus also have observed immune responses to
OVA alone but most of these experiments used adjuvants
like alum, and very likely had LPS in the OVA. Also the
OVA was administered intranasally, a practice which leads
to fluid accumulation and potentially immunostimulating
organisms into the lower respiratory tract. The exception is
the report by O’Donnell, where OVA was administered
by aerosol and OVA-specific antibodies were only ob-
served if given during virus infection (25); the endotoxin
contamination was not determined in this study, however.
In the current study, we used an endotoxin free OVA
preparation and gave the antigen as a small particle aerosol
mist without any adjuvants. Under these circumstances,
influenza virus coinfection and DC maturation were asso-
ciated with the induction of strong OVA-specific immu-
nity to the otherwise nonimmunogenic protein. There-
fore, influenza-associated, DC maturation likely has a
pivotal role in initiating immunity, although it remains im-
portant experimentally to develop the means to selectively
block maturation in the presence of infection to certify
that immunity will not develop.
The Danger of Infection-induced DC Maturation and a Solu-
tion via Immature DCs. Our results demonstrate that respi-
ratory virus infection is altering the response to a non-
related harmless antigen, such as endotoxin-free OVA, to
allow for the generation of a strong Th1 response. This il-
lustrates the risk to DC maturation, which is that during
infection, DCs, at least at the population level, should cap-
ture and present a mix of microbial antigens, innocuous
self-antigens, and environmental proteins. This capacity of
DCs to induce strong cell-mediated immunity to an other-
wise harmless airway protein during infection was shown
by the production of high levels of IFN-  and IL-2 from
OT-I and OT-II T cells infused into animals that received
OVA protein in the presence of virus infection (but not
when OVA alone was administered; Fig. 3). In light of the
results showing that OVA peptides were presented in both
instances, without or with influenza infection, the alter-
ations in the functional T cell outcome likely results from
the maturation of the DCs. The cells involved in present-
ing antigen in the draining lymph nodes were CD11c 
cells (Fig. 4) and as such, very likely to be DCs (40, 41). As
mentioned above, when we did kinetic studies, CD11c 
DCs (but not B cells and macrophages, Fig. 5) collected
from the draining lymph nodes of infected mice showed a
strong up-regulation of MHC class II, as well as costimula-
tory molecules such as CD80 and CD86. This became de-
tectable by 45 h after infection, peaked at 72 h and was no
longer evident at 7 d, even though virus was still present in
the lungs at this juncture. Interestingly, when a single dose
of OVA was administered at various time points beginning
at the time of virus infection and continuing until day 10,
the ability of influenza virus infection to promote a re-
sponse to OVA correlated exactly with the presence in the
lymph nodes of mature CD11c  cells. Several stimuli could
contribute to influenza virus–induced maturation of DCs,
including inflammatory cytokines like TNF and IL-1, type
I interferons, and TLR3 signaling.
The DCs within lymphoid tissues in the steady-state
seem able to deal with the dilemma that is inherent in DC
maturation. These DCs can capture and process antigens to
form MHC–peptide complexes (Figs. 2 and 3), but the T
cells can be tolerized, e.g., by deletion (29, 31, 33). In the
studies of Umetsu’s group, intranasal OVA induced a lim-
ited form of tolerance in which IgE antibody responses
were ablated (36) but IgG responses were not and IL-10
producing regulatory T cells were induced (27). These
mechanistic possibilities were not directly analyzed here.
What is emphasized here is the capacity of immature DCs
in lymph nodes to capture and present LPS-free and nor-
mally nonimmunogenic proteins from the airway, so effi-
ciently that the initial T cell proliferative response is sub-
stantial even when compared with the OVA–T cell
responses in influenza virus infection. However, unless the
animals are also infected with influenza virus, the OVA-
specific T cells do not differentiate to produce cytokines,
become killer cells, or help for antibody formation. The
steady-state functions of DCs in lymphoid tissues seem crit-
ical for defining immunologic self and ensuring that the T
cell repertoire is conditioned such that immunity to self and
environmental proteins does not develop when DCs are
called upon to mature and present microbial antigen. Oth-
erwise, harmless proteins would induce combined B and T
immunity when inhaled during an infection like influenza.
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